After the White House used a Sabrina Carpenter song without her permission, the pop star is keeping her response short and sweet. The "Espresso" singer, 26, took to X to slam the White House for using ...

To better understand which social media platforms Americans use, Pew Research Center surveyed 5,022 U.S. adults from Feb. 5 to June 18, 2025. SSRS conducted this National Public Opinion Reference ...

Kenny Loggins is speaking out against President Donald Trump's use of his song "Danger Zone" in an AI video responding to widespread No Kings protests. In response, Loggins said in a statement shared ...

Teachers’ and students’ use of artificial intelligence in K-12 classrooms is increasing at a rapid pace, prompting serious concerns about the potentially negative effects on students, a new report ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

As chatbots powered by artificial intelligence explode in popularity, experts are warning people against turning to the technology for medical or mental health advice instead of relying upon human ...

The president said later that he was not aware of the term's connotation. Jewish advocacy groups slammed President Donald Trump for using an anti-Semitic descriptor on Thursday during his Iowa speech ...

Either way, let’s not be in denial about it. Credit...Illustration by Christoph Niemann Supported by By Kevin Roose and Casey Newton Kevin Roose and Casey Newton are the hosts of The Times’s “Hard ...

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day supply. The FDA has approved Sanofi’s Merilog (insulin-aspart-szjj) as a ...

The U.S. Food and Drug Administration (FDA) has approved Merilog, a biosimilar to the widely used insulin product Novolog (insulin aspart), to enhance glycemic control in adults and children with ...

More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has ...